4.6 Article

Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance

期刊

CANCER MEDICINE
卷 4, 期 1, 页码 155-160

出版社

WILEY
DOI: 10.1002/cam4.324

关键词

Prognostic model; stage I seminoma; surveillance

类别

向作者/读者索取更多资源

A prognostic model for relapse risk in stage I seminoma managed by surveillance after orchiectomy has been developed but has not been independently validated. Individual data on 685 stage I seminoma surveillance patients managed between 1998 and 2005 at three cancer centers were retrospectively analyzed. Variables including age and pathology of the primary tumor: small vessel invasion, tumor size, and invasion of rete testis were analyzed. Specifically median tumor size and rete testis invasion was tested to evaluate the performance of the published model. Median follow-up was 3.85 years (0.1-10.29), 88 patients relapsed and 5-year relapse-free rate was 85%. In univariate analysis, median tumor size (< 3 cm vs. >= 3 cm) was associated with increased risk of relapse but rete testis invasion was not, nor was age and small vessel invasion. In multivariable analysis, tumor size above median (cutpoint of 3 cm) was a predictor for relapse, HR 1.87 (95% CI 1.15, 3.06), whereas rete testis invasion HR 1.36, (95% CI 0.81, 2.28) was not statistically significant. The 3-year relapse risk based on the primary tumor size alone increased from 9% for 1 cm primary tumor to 26% for 8 cm tumor. A clinically useful, highly discriminating prognostic model remains elusive in stage I seminoma surveillance as we were unable to validate the previously developed model. However, primary tumor size retained prognostic importance and a scale of relapse risk based on the unit increment of tumor size was developed to help guide patients and clinicians in decision making.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

The effectiveness of psychoeducational interventions on caregiver-oriented outcomes in caregivers of adult cancer patients: A systematic review and meta-analysis

Grace Kusi, Eshetu G. Atenafu, Adwoa Bemah Boamah Mensah, Charlotte T. Lee, Auro Viswabandya, Martine Puts, Samantha Mayo

Summary: Psychoeducational intervention (PEI) has a positive effect on cancer caregivers, reducing caregiver burden, improving quality of life, and reducing anxiety and depression. The study also found that intervention characteristics such as studies conducted in high-income countries, group interventions, and studies focused on specific and mixed cancers can impact the effectiveness of the intervention.

PSYCHO-ONCOLOGY (2023)

Letter Hematology

Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR-ABL negative myeloproliferative neoplasms

Marta Davidson, Florence Wong, Mostafa Atri, Hassan Sibai, Dawn Maze, Verna Cheung, Jeannie Callum, Eshetu G. Atenafu, Vikas Gupta

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Biophysics

Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults

Maria Queralt Salas, Eshetu G. G. Atenafu, Ivan Pasic, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Arjun Datt Law, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Kim, Armin Gerbitz, Auro Viswabandya, Fotios V. V. Michelis, Jeffrey Howard Lipton, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar

Summary: This study designs an HCT Frailty Scale to classify alloHCT candidates into different frailty groups, which can be implemented in the first consultation without additional cost. The scale uses eight variables to assess and calculate the frailty score of a patient, which can predict the one-year overall survival rate. The scale is a low-cost and highly informative prognostic signal for outcomes at the pre-transplant stage.

BONE MARROW TRANSPLANTATION (2023)

Article Oncology

Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?

Sahar Khan, Donna Reece, Eshetu G. Atenafu, Sita Bhella, Christine Chen, Esther Masih-Khan, Harminder Paul, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti

Summary: A retrospective evaluation was conducted on 106 multiple myeloma patients who underwent upfront therapy with PI based induction and ASCT (+/- IMiD maintenance) to assess the outcome of salvage ASCT. At a median follow-up of 26 months, the estimated median PFS and OS were 24 and 80 months respectively. PFS post ASCT1 of at least 42 months and IMiD non-refractory disease were associated with improved outcome.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Article Oncology

Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency

Davidson Zhao, Entsar Eladl, Mojgan Zarif, Jose-Mario Capo-Chichi, Andre Schuh, Eshetu Atenafu, Mark Minden, Hong Chang

Summary: This study retrospectively evaluated 266 AML-MRC patients and found that TP53(MUT) AML-MRC is a very-high-risk subtype of AML with poor prognosis. Patients with high TP53(MUT) variant allele frequency had worse outcomes. TP53 mutations and elevated serum LDH were independent predictors for inferior prognosis.

CANCER MEDICINE (2023)

Article Hematology

Impact of geographical distance from quaternary treatment center on clinical trial participation, intensive induction chemotherapy, and outcomes in patients with newly diagnosed AML

Samantha A. Hershenfeld, Eshetu G. Atenafu, Steven Chan, Vikas Gupta, Dawn Maze, Andre Schuh, Hassan Sibai, Karen Yee, Aaron Schimmer

Summary: This study found that distance from the treatment center did not significantly affect the choice of upfront therapy, participation in clinical trials, or clinical outcomes for patients with acute myeloid leukemia (AML) in Ontario's single payer healthcare system.

ACTA HAEMATOLOGICA (2023)

Article Oncology

Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial

P. L. Jorgensen, M. Kreiberg, N. Jorgensen, A. Juul, P. S. Oturai, C. Dehlendorff, J. Lauritsen, T. Wagner, J. Rosenvilde, G. Daugaard, C. R. Medici, N. R. Jorgensen, M. Bandak

Summary: The aim of this study was to evaluate the metabolic profile and bone mineral density (BMD) changes in testicular cancer survivors with mild Leydig cell insufficiency after 12 months of testosterone replacement therapy (TRT). The results showed that TRT did not significantly affect BMD, but it resulted in a small increase in N-terminal propeptide of type 1 procollagen (P1NP), which had little clinical significance.

ACTA ONCOLOGICA (2023)

Article Hematology

Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor

James T. T. England, Eshetu G. G. Atenafu, James A. A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia

RuiQi Chen, Eshetu G. Atenafu, Jack Seki, Xing Liu, Steven Chan, Vikas Gupta, Dawn Maze, Andre C. Shuh, Mark D. Minden, Karen Yee, Aaron D. Schimmer, Hassan Sibai

Summary: This study found that PEG-ASP is associated with a higher incidence of VTE compared to L-ASP in patients with ALL, despite prophylactic anticoagulation. Further VTE mitigation strategies are needed for adult patients receiving PEG-ASP.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Dose-dependent efficacy of bevacizumab in recurrent glioblastoma

Jawad M. Melhem, Ali Tahir, Eirena Calabrese, Inga Granovskaya, Eshetu G. Atenafu, Arjun Sahgal, Mary Jane Lim-Fat, James R. Perry

Summary: This study aimed to validate the safety and efficacy of low-dose bevacizumab (BEV) for patients with recurrent glioblastoma (rGBM). The study found that compared to the standard dose regimen, low-dose BEV was associated with significantly prolonged overall survival and progression-free survival. Lower dose schedules may be a better and more cost-effective option, providing more equitable access to the palliative drug.

JOURNAL OF NEURO-ONCOLOGY (2023)

Article Clinical Neurology

30 Gy in 4 Stereotactic Body Radiotherapy Fractions for Complex Spinal Metastases: Mature Outcomes Supporting This Novel Regimen

Daniel Moore-Palhares, Arjun Sahgal, K. Liang Zeng, Sten Myrehaug, Chia-Lin Tseng, Jay Detsky, Hanbo Chen, Mark Ruschin, Eshetu G. Atenafu, Jeff Wilson, Jeremie Larouche, Leodante da Costa, Pejman Jabehdar Maralani, Hany Soliman

Summary: This study reports the outcomes of a novel fractionation scheme, 30 Gy in 4 fractions, for the treatment of spinal metastases. The results show that this approach is safe and effective, especially for patients with a clinical target volume (CTV) volume of ≥72 cc.

NEUROSURGERY (2023)

Article Multidisciplinary Sciences

A longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT): Protocol for a phase II feasibility pilot randomized controlled trial

Samantha Tam, Rajat Kumar, Paty Lopez, Jonas Mattsson, Shabbir Alibhai, Eshetu G. Atenafu, Lori J. Bernstein, Eugene Chang, Susan Clarke, David Langelier, Jeffrey Lipton, Samantha Mayo, Tina Papadakos, Jennifer Michelle Jones

Summary: This study aims to develop a 6-month rehabilitation program for patients undergoing alloBMT and test the feasibility and acceptability of the program through a randomized controlled trial. It will also collect secondary clinical outcomes to inform future research.

PLOS ONE (2023)

Article Oncology

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

Davidson Zhao, Mojgan Zarif, Qianghua Zhou, Jose-Mario Capo-Chichi, Andre Schuh, Mark D. Minden, Eshetu G. Atenafu, Rajat Kumar, Hong Chang

Summary: TP53 mutations are adverse-risk genetic aberrations in acute myeloid leukemia (AML). The optimal treatment approach for patients with TP53-mutated (TP53(MUT)) AML remains unclear. This study aimed to evaluate the prognostic implications of different frontline treatment strategies and transplantation for patients with TP53(MUT) AML. The results suggest that current therapeutic strategies are ineffective for TP53(MUT) AML patients, highlighting the urgent need for new treatment strategies for this high-risk population.

CANCERS (2023)

Article Oncology

High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Nazanin Aghel, Dakota Gustafson, Diego Delgado, Eshetu G. Atenafu, Jason E. Fish, Jeffrey H. Lipton

Summary: Tyrosine kinase inhibitors (TKIs) have had a significant impact on the treatment of chronic myelogenous leukemia (CML), but they may have cardiovascular toxicities. This study examined the relationship between the marker hsCRP and vascular dysfunction markers with exposure to specific TKIs in CML patients. The results showed that hsCRP levels were not associated with disease activity or treatment with specific TKIs, but other markers of vascular dysfunction were altered in patients treated with certain TKIs.

LEUKEMIA & LYMPHOMA (2023)

Article Rheumatology

Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis

Sonya T. Kim, Carolina Munoz-Grajales, Shannon E. Dunn, Raphael Schneider, Sindhu R. Johnson, Zahi Touma, Zareen Ahmad, Dennisse Bonilla, Eshetu G. Atenafu, Linda T. Hiraki, Arthur Bookman, Joan Wither

Summary: It has been found that measuring the levels of IFN-alpha in serum can accurately predict the immune-induced gene expression in ANA(+) individuals and be used for clinical prediction. At the same time, measuring the levels of CXCL-10 and Galectin-9 can also predict the progression of the disease in ANA(+) individuals.

ARTHRITIS RESEARCH & THERAPY (2023)

暂无数据